-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Piper Sandler Downgrades Fate Therapeutics to Neutral, Lowers Price Target to $12

Benzinga · 01/06/2023 05:03
Piper Sandler analyst Edward Tenthoff downgrades Fate Therapeutics (NASDAQ:FATE) from Overweight to Neutral and lowers the price target from $71 to $12.